<DOC>
	<DOCNO>NCT02110901</DOCNO>
	<brief_summary>This research study design assess safety effectiveness experimental drug call PRT-201 patient receive expect receive dialysis chronic kidney disease undergo surgery create new access point bloodstream hemodialysis . PRT-201 protein show previous research study help keep vessel patent apply outside surface blood vessel ( artery vein ) patient undergo surgery create arteriovenous fistula ( AVF ) . The purpose study determine whether PRT-201 apply limited segment blood vessel ( 2 inch ) immediately surgery safe improves patency AVF .</brief_summary>
	<brief_title>A Study PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula ( AVF ) Creation Patients With Chronic Kidney Disease ( CKD ) ( PATENCY-1 )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<criteria>1 . Age least 18 year . 2 . Life expectancy least 6 month . 3 . Diagnosis Chronic Kidney Disease ( CKD ) . 4 . Planned creation new radiocephalic arteriovenous fistula ( AVF ) revision exist AVF eligible . 5 . Ability understand comply requirement entire study communicate study team . 6 . Written inform consent use document approve Institutional Review Board ( IRB ) . 7 . If female childbearing potential ( premenopausal surgically sterile ) must negative serum pregnancy test screen visit ( Visit 1 ) willing use contraception time screen visit 2 week follow study drug administration . Acceptable method birth control include abstinence , barrier method , hormone , intra uterine device . 1 . Malignancy treatment malignancy within previous 12 month exception follow cancer resect : localize basal cell squamous cell skin cancer , cancer situ . 2 . Presence significant medical condition might significantly confound collection safety efficacy data study . 3 . Previous treatment PRT 201 . 4 . Treatment investigational drug within previous 30 day investigational antibody therapy within previous 90 day prior sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>radiocephalic</keyword>
	<keyword>arteriovenous fistula</keyword>
	<keyword>AVF</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>PRT-201</keyword>
	<keyword>vascular access</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>vonapanitase</keyword>
	<keyword>PATENCY-1</keyword>
</DOC>